|Bid||70.00 x 1000|
|Ask||70.54 x 3200|
|Day's Range||69.68 - 70.56|
|52 Week Range||56.56 - 73.34|
|Beta (5Y Monthly)||0.41|
|PE Ratio (TTM)||17.13|
|Earnings Date||Oct. 26, 2021 - Nov. 01, 2021|
|Forward Dividend & Yield||2.84 (3.99%)|
|Ex-Dividend Date||Sep. 14, 2021|
|1y Target Est||75.84|
In the latest trading session, Gilead Sciences (GILD) closed at $69.97, marking a -0.62% move from the previous day.
FOSTER CITY, Calif., September 27, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior therapies, at least one of them for metastatic disease. Canada joins Australia, Great Britain, Switzerland, and the United States among the countries that have approved Trodelvy
Dr. Manish Garg, Emergency Medicine Physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.